{
    "title": "111_s1315",
    "content": "The Drug Price Competition Act of 2009 is also known as the \"Drug Price Competition Act\". It amends Section 505(j)(5) of the Federal Food, Drug, and Cosmetic Act to define the term \"first applicant\". The Drug Price Competition Act of 2009, also known as the \"Drug Price Competition Act,\" defines a first applicant as an applicant who submits a substantially complete application containing a specific certification for drug approval. The Drug Price Competition Act of 2009 defines a first applicant as one who maintains a certification for the drug. The Drug Price Competition Act of 2009 defines a first applicant as one who satisfies the requirements for the drug not described in item (AA). The Drug Price Competition Act of 2009 defines a first applicant as one who satisfies the requirements for the drug not described in item (AA). An applicant described in subclause (II)(bb)(BB) must submit and maintain a certification or statement for each unexpired patent previously submitted by a first applicant described in item (AA). The Drug Price Competition Act of 2009 defines a first applicant as one who satisfies the requirements for the drug not described in item (AA). An applicant described in subclause (II)(bb)(BB) must submit and maintain a certification or statement for each unexpired patent previously submitted by a first applicant described in item (AA). Paragraph (2)(A)(vii)(IV) states that no action for patent infringement should be brought against the applicant within the specified 45-day period after submitting a substantially complete application with the certification. The applicant must obtain a court decision within the specified time period that the patent is invalid or not infringed, including settlement orders or consent decrees. The court must sign a consent decree stating the patent is invalid or not infringed. The applicant can receive immediate approval before others start marketing. In subsection (a), amendments are made to clauses regarding the definition of the first applicant and the forfeiture of the 180-day exclusivity period. The effective date of these amendments is specified in subsection (b). The amendments made by subsection (a) are effective only for applications filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act to which the amendments made by section 1102(a) of the Medicare Prescription Drug Improvement and Modernization Act of 2003 apply. An application without the 180-day exclusivity period and containing a specific certification will be treated as a previous application under certain conditions. The text discusses the conditions under which a patent infringement action can be brought against an applicant under section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act. It mentions that if no action is taken within the specified 45-day period or if a court determines the patent is invalid or not infringed, the applicant is exempt from infringement claims. The text discusses the conditions for immediate approval of a patent application under certain provisions of the Federal Food, Drug, and Cosmetic Act. This includes situations where a settlement order declares the patent invalid or not infringed, and no other applicant has started commercial marketing."
}